适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- CDR-Life AG
- 入组人数
- 91
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- 干预性
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
标识符
- 注册编号
- CTIS2023-508808-38-00
- 其他研究编号
- 1111-1299-0120
日期
- 最近更新
- (2年前)
监管与共享
- 是否有结果
- 否
相似试验
招募中
1 期
A clinical trial to learn how an investigational drug (vimseltinib) is absorbed, distributed, broken down, and removed from the body when given to people with liver problemsMedDRA version: 21.1Level: PTClassification code: 10018255Term: Giant cell tumour of tendon sheath Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104Tenosynovial Giant Cell Tumor (TGCT), Malignant Solid Tumors (MST)MedDRA version: 21.0Level: LLTClassification code: 10018253Term: Giant cell tumor of tendon sheath Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10010014Term: Colony stimulating factor therapy Class: 100000004865CTIS2023-503415-15-00Deciphera Pharmaceuticals Inc.48
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48